与其他多发性硬化症口服治疗方法相比,cladribine片的有效性简要概述:MSBase注册表的结果
Tim Spelman1, Serkan Ozakbas2, Raed Alroughani3
1MSBase Foundation, Melbourne, Australia.
Neurodegenerative disease management
|June 8, 2023
概括
克拉迪宾片 (Mavenclad®) 在多发性硬化症 (MS) 患者中,与其他口服MS疗法相比,显示了更长的治疗坚持和更少的复发. 这些发现凸显了克拉迪宾片作为一种有效的口服治疗选择,用于管理MS.
科学领域:
- 神经学 神经学
- 临床研究 临床研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 患者登记册提供了有关医疗状况的宝贵现实数据.
- 在MSBase注册表中,全球有超过8万名患有多发性硬化症 (MS) 的人的匿名数据.
- 现实世界的证据对于评估不同患者群体的治疗有效性至关重要.
研究的目的:
- 为了比较cladribine片 (Mavenclad®) 与其他口服治疗MS的实际结果.
- 评估在接受克拉德里宾片治疗的MS患者的治疗坚持和复发率,与替代口服疗法相比.
- 为了评估克拉德里宾片在一个大规模的国际多发性硬化症患者队列中的有效性.
主要方法:
- 利用了MSBase患者登记的数据,包括超过8万名MS患者.
- 分析了3,475名MS患者的结局,与其他口服MS药物治疗患者相比,他们接受了克拉德里宾片治疗.
- 该GLIMPSE (在多发性结核病中产生学习) 研究专注于真实世界的数据.
主要成果:
- 与其他口服MS疗法相比,用克拉迪宾片治疗的患者的治疗持续时间较长.
- 在克拉迪布林片组与替代口服治疗组相比,在克拉迪布林片组观察到的复发 (症状发作) 较少.
- 这些结果表明,在MS治疗中,克拉德里宾片在现实世界中具有有利的有效性.
结论:
- 克拉德里宾片是多发性硬化症患者的有效口服药物.
- 该研究提供了证据支持使用克拉德里宾片改善治疗坚持和减少复发率在MS.
- 来自MSBase注册表的现实数据证实了克拉迪宾片剂与其他口服MS治疗相比的疗效.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
204
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
204
Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K


